Marc de Garidel

Marc de Garidel

Chief Executive Officer and Member of the Board of Directors

AZTherapies, Inc.

Prior to joining AZTherapies, Mr. de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in July 2020 for $2.1 billion. From 2010 to 2016, he served as Chairman and CEO of Ipsen SA, where he led a significant transformation of Ipsen, effecting a three-fold increase in market capitalization, launching the blockbuster oncology drug Somatuline Depot (lanreotide) in the U.S., and completing the ex-U.S. commercialization deal with Exelixis on CABOMETYX (cabozantinib). Mr. de Garidel continues to serve as Chairman of the Ipsen Board of Directors. Prior to that, Mr. de Garidel spent 15 years at Amgen, initially joining as the company’s Chief Financial Officer in Europe and ultimately leading the South Region of Amgen International, responsible for operations across most of Europe and Latin America. He began his career at Eli Lilly and Company, where he worked in the U.S., France, and Germany in a variety of roles in sales, marketing, finance, and human resources. Mr. de Garidel received a Master’s degree in Civil Engineering from ETP in Paris, a Master’s degree in Management from the Thunderbird School of Global Management, and completed the Advanced Management Program (Executive MBA) at Harvard Business School.